Leone M, Attanasio A, Croci D, Filippini G, D'Amico D, Grazzi L, Nespolo A, Bussone G
Istituto Nazionale Neurologico Carlo Besta, Milan, Italy.
Neurology. 2000 Jul 12;55(1):136-9. doi: 10.1212/wnl.55.1.136.
In a double-blind study versus placebo, the serotonergic agent m-chlorophenylpiperazine (mCPP) was administered to 20 healthy control subjects and 19 migraineurs to investigate the ability of mCPP (0.5 mg/kg) to induce typical migraine attacks. In the following 24 hours there were more migraines after mCPP than after placebo in both groups. These findings are consistent with involvement of 5HT2B,2C,1A receptor subtypes in the pathophysiology of migraine.
在一项与安慰剂对照的双盲研究中，向20名健康对照者和19名偏头痛患者给予血清素能药物间氯苯哌嗪（mCPP），以研究mCPP（0.5毫克/千克）诱发典型偏头痛发作的能力。在接下来的24小时内，两组中服用mCPP后的偏头痛发作次数均多于服用安慰剂后。这些发现与5HT2B、2C、1A受体亚型参与偏头痛的病理生理学过程一致。
